tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Celgene Corp.'

Drug Makers Could Soon Turn Away From Eli Lilly’s Gemzar and Toward Nuvilex’s Cell Encapsulation

Drug Makers Could Soon Turn Away From Eli Lilly’s Gemzar and Toward Nuvilex’s Cell Encapsulation

Written by ι Stock Market Media Group Staff — August 22, 2013

While Eli Lilly’s (NYSE: LLY) cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big pharmaceutical companies are combining their own drugs with  gemcitabine in their own clinical trials in an attempt to improve upon the gemcitabine’s effectiveness when that drug is used alone for the treatment of advanced, inoperable pancreatic cancer, but they’re not finding much success.  ...

Read More →
0

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Nuvilex, Inc. a Biotech Developing Treatments for Healthcare’s Hard Targets

Written by ι Stock Market Media Group Staff — June 26, 2013

Nuvilex, Inc. (OTCQB: NVLX) executives aren’t daunted by the statistics.  As a matter of fact, they’re aware the research they do is directed towards attacking what the company’s Chief Operations Officer, Dr. Gerald Crabtree, calls two of cancer’s “hard targets.”  “Pancreatic cancer and brain cancers represent two such targets.  Pancreatic cancer because it doesn’t present overt symptoms until the cancer is at an advanced stage; therefore, it is more difficult to ...

Read More →
0

Nuvilex, Inc.’s Phase III Pancreatic Cancer Trials Could Address New Law’s Call for Progress

Nuvilex, Inc.’s Phase III Pancreatic Cancer Trials Could Address New Law’s Call for Progress

Written by ι Stock Market Media Group Staff — June 24, 2013

Nuvilex, Inc. (OTCQB: NVLX) has a great opportunity to demonstrate and showcase its encapsulation technology in its upcoming Phase III clinical trials for the treatment of late stage, inoperable pancreatic cancer.  There will be plenty of interested observers, and you can bet that those US Senators and Congressmen responsible for the Recalcitrant Cancer Research Act that was signed into law earlier this year, will be among them.

Nuvilex’s upcoming late stage ...

Read More →
0

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Written by ι Stock Market Media Group Staff — May 20, 2013

The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner’s treatment.  Two biotechnology companies are registering impressive data in each of their own pancreatic cancer trials, so impressive in fact, Eli Lilly & Co. (NYSE: LLY) is surely feeling its long time reign as the current standard single-drug treatment for the disease being threatened.  Nuvilex, Inc. (OTCQB: NVLX) and Celgene Corp. (NASDAQ: ...

Read More →
0

Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer

Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer

Written by ι Stock Market Media — March 5, 2013

In late January, those with advanced stage pancreatic cancer received some good news when Celgene, Corp (NASDAQ: CELG) announced the results of its large scale phase III trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), held in San Francisco. 

Pancreatic cancer is difficult to diagnose and treat until it is at an advanced stage.  Survival of patients with advanced, inoperable pancreatic cancer ...

Read More →
0

Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity than Competitors

Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity than Competitors

Written by ι Stock Market Media Group Staff — May 2, 2013

Nuvilex, Inc. (OTCQB: NVLX) has already produced impressive results from its two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer.  Two key results pulled from the data of those trials, are that the median survival rate was higher than that of the current gold standard for the disease and better than those of other competitors’ treatments when clinical trial reports are examined.  Furthermore, the overall side-effect profile ...

Read More →
0
ContactUs.com